Skip to main navigation
Tenaya Therapeutics
  • Careers at Tenaya
  • Contact Us
  • Leadership
  • Our Science
    • Platforms
    • Capabilities
    • Collaborations
    • Publications & Presentations
  • Our Programs
    • Pipeline
    • Programs
  • Patients
    • Elevating Patient Voices
    • Advocacy at Tenaya
    • Clinical Studies
    • Gene Therapy for Cardiomyopathies
    • Advocacy Partners
  • Investors
    • News & Events
      • Press Releases
      • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
    • Financial Information
      • SEC Filings
      • Quarterly Results
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • IR Resources
      • Investor FAQs
      • Contact IR
      • Email Alerts
  • HCP Resource Center
    • Genetic Medicine Primer
      • About Gene Therapy
    • TN-201 for MYBPC3– associated HCM
      • Hypertrophic Cardiomyopathy and Genetics
      • How TN-201 Works
      • MyPEAK-1 Phase 1b/2 Clinical Trial
      • Tenaya’s Non-interventional Studies for MYBPC3 HCM
      • Webinars
      • FAQ’s
    • TN-401 for PKP2– associated ARVC
      • ARVC and Genetics
      • How TN-401 works
      • RIDGE-1 Phase 1b Clinical Trial
      • Tenaya’s Non-interventional Study for PKP2-Associated ARVC
      • FAQ’s

Investor Portal

Document Details

Form
10-Q
Filing Date
May 7, 2025
Document Date
Mar 31, 2025
Form Description
Quarterly report which provides a continuing view of a company's financial position
Filing Group
Quarterly Filings
Company
Tenaya Therapeutics, Inc.
Issuer
TENAYA THERAPEUTICS, INC.

Filing Formats

iXBRL
View HTML
Download PDF
Download DOC
Download XLS

XBRL

XBRL Viewer
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
XML - XBRL INSTANCE DOCUMENT
RSS Feeds
Email Alerts
Contact IR
Print

Privacy Policy | Cookie Policy | Terms of Use | Community Guidelines
© 2026 Tenaya Therapeutics. All rights reserved.